Nuveen’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-94,039
| Closed | -$9.59M | – | 3251 |
|
|
2023
Q2 | $9.59M | Sell |
94,039
-17,082
| -15% | -$1.62M | ﹤0.01% | 1538 |
|
|
2023
Q1 | $10.1M | Buy |
111,121
+4,006
| +4% | +$235K | ﹤0.01% | 1476 |
|
|
2022
Q4 | $4.07M | Sell |
107,115
-3,318
| -3% | -$114K | ﹤0.01% | 2028 |
|
|
2022
Q3 | $2.77M | Sell |
110,433
-3,213
| -3% | -$89K | ﹤0.01% | 2222 |
|
|
2022
Q2 | $3.45M | Buy |
113,646
+8,114
| +8% | +$242K | ﹤0.01% | 2162 |
|
|
2022
Q1 | $3.99M | Buy |
105,532
+8,117
| +8% | +$241K | ﹤0.01% | 2170 |
|
|
2021
Q4 | $2.57M | Sell |
97,415
-7,421
| -7% | -$574K | ﹤0.01% | 2447 |
|
|
2021
Q3 | $10.5M | Sell |
104,836
-61,631
| -37% | -$7.22M | ﹤0.01% | 1741 |
|
|
2021
Q2 | $23.6M | Buy |
166,467
+37,961
| +30% | +$4.29M | 0.01% | 1238 |
|
|
2021
Q1 | $12.8M | Buy |
128,506
+2,001
| +2% | +$233K | ﹤0.01% | 1638 |
|
|
2020
Q4 | $15.6M | Buy |
126,505
+25,285
| +25% | +$3.32M | 0.01% | 1407 |
|
|
2020
Q3 | $9.86M | Sell |
101,220
-9,760
| -9% | -$1.22M | ﹤0.01% | 1534 |
|
|
2020
Q2 | $17.3M | Sell |
110,980
-77,895
| -41% | -$11.8M | 0.01% | 1140 |
|
|
2020
Q1 | $27.3M | Buy |
188,875
+24,949
| +15% | +$4.82M | 0.01% | 736 |
|
|
2019
Q4 | $33.5M | Sell |
163,926
-10,239
| -6% | -$1.87M | 0.01% | 878 |
|
|
2019
Q3 | $14M | Buy |
174,165
+38,853
| +29% | +$3.3M | 0.01% | 1352 |
|
|
2019
Q2 | $12.8M | Buy |
135,312
+130,494
| +2,708% | +$11.3M | 0.01% | 1449 |
|
|
2019
Q1 | $412K | Buy |
+4,818
| New | +$400K | ﹤0.01% | 865 |
|
Other funds holding RETA
Nuveen's RETA Position: Q3 2023 in Review
Nuveen sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 94,039 shares — an estimated $9.59M sold.
Nuveen first reported a position in RETA in Q1 2019 and held it in 18 quarters. The position peaked at $33.5M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Nuveen reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Nuveen sold 94,039 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $9.59M.
- Nuveen first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 18 quarters.
- Nuveen's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $33.5M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Nuveen's 13F filing for Q3 2023, filed 14 Nov 2023.